Voi, Maurizio

Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma

Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 1,389

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., et al. (2016) · The Lancet

Tuberous Sclerosis Complex ResearchEpilepsy research and treatment

Cited by 764

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

Qian, C., Lai, C.-J., Bao, R., Wang, D.-G., Wang, J., Xu, G.-X., Atoyan, R., Qu, H., Yin, L., Samson, M., et al. (2012) · Clinical Cancer Research

Histone Deacetylase Inhibitors ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 248

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

Demetri, G. D., Lo Russo, P., MacPherson, I. R. J., Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agrawal, S., Voi, M., & Evans, T. R. J. (2009) · Clinical Cancer Research

Cancer therapeutics and mechanismsLung Cancer Treatments and Mutations

Cited by 150

Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial

Franz, D. N., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Voi, M., et al. (2018) · Neurology Clinical Practice

Tuberous Sclerosis Complex ResearchEpilepsy research and treatment

Cited by 108